Piper Jaffray Remains Bullish on Lam Research (LRCX) as Technology Inflections Continue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Notable Analyst Rating Changes 10/5: (TWTR) (FOLD) (JNPR) Upgraded; (SNI) (LRCX) (FEYE) Downgraded
October 5, 2015 10:24 AM EDTUPGRADES
Axiom Capital upgraded Twitter, Inc. (NYSE: TWTR) from Hold to Buy with a price target of $37.
Chardan Capital Markets upgraded Amicus Therapeutics (Nasdaq: FOLD) from Neutral to Buy with a... More
Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)
October 5, 2015 9:24 AM EDTSpark Therapeutics (NASDAQ: ONCE) 37.4% HIGHER; announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.
American Apparel, Inc. (NYSE: APP) 24% LOWER; files Chapter 11
AmicusTherapeutics... More
RBC Capital Downgrades Lam Research (LRCX) to Underperform
October 5, 2015 6:25 AM EDTRBC Capital downgraded Lam Research (NASDAQ: LRCX) from Sector Perform to Underperform with a price target of $52.00 (from $76.00).
Analyst Mahesh Sanganeria commented, "We estimate CY16 total capex will be down 13% yoy to $46B, driven by 38% decline in DRAM capex, 17% drop in NAND spending,... More
